March 15th 2023
Session moderators, speakers and audience members all will examine and analyse the most relevant and controversial issues within the field of ophthalmology.
Angiogenesis 2023: Study examines GA phenotypes and progression rates in Asians, non-AsiansFebruary 10th 2023
A study conducted by Gemmy Cheung, MBBS, FRCOphth and colleagues shows geographic atrophy (GA) lesion phenotypes, associated features, and growth rates differ between Asians and non-Asians.
Retinal imaging to detect Alzheimer disease: machine learning model
An interdisciplinary team at Duke University has developed a proof-of-concept machine learning model capable of detecting symptomatic Alzheimer disease using multimodal retinal imaging data.
Dry AMD: A review of ongoing, completed and future treatmentsFebruary 2nd 2023
The most promising recent interventional trials for investigational therapies in dry age-related macular degeneration are highlighted by the authors.
Finding the clues: What retinal vasculature changes may mean for cognitive impairmentJanuary 13th 2023
Ultra-widefield imaging may be a promising technology for assessing larger areas of the retinal vasculature to uncover retinal changes in Alzheimer’s disease, according to investigators.
2023: What ophthalmologists in Europe anticipate for the year aheadDecember 12th 2022
Members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests for 2023. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.
Faricimab approved for treatment of nAMD, DMO by European CommissionSeptember 19th 2022
Roche’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.
Fluid monitor utilises AI to identify, localise and quantify retinal fluidSeptember 7th 2022
Eyecare specialists benefit from being able to monitor their patients long term for optimised and personalised treatment regimens, as well as having access to a more efficient workflow and one which enables them to see more patients.
Multicentre Phase 3 clinical trial using AI in nAMD identifies, measures fluid volumes in real timeSeptember 6th 2022
According to Dr Gregor S. Reiter, the results from the multicentre Phase 3 clinical trial demonstrated that fluid volumes in patients with nAMD can be precisely identified, localised and measured in real-time using artificial intelligence.
Gene therapies licensed by Kriya Therapeutics target geographic atrophy, other ocular diseasesFebruary 18th 2022
Kriya Therapeutics company recently took the wraps off an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.
Avacincaptad pegol slows growth of geographic atrophy lesions for patients in clinical trialFebruary 11th 2022
In a presentation at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation and Degeneration 2022 Virtual Edition, Dr Glenn J. Jaffe noted that the analysis showed, for the first time, a decreased growth rate in the central foveal area by a therapeutic intervention when compared with sham treatment.
Subretinal implant for advanced dry AMD determined to be safe, well-toleratedFebruary 11th 2022
This study showed that an investigational subretinal implant, CPCB-RPE1, containing allogeneic human embryonic stem cell-derived RPE cells, was safe and well-tolerated by patients with dry AMD.
Blocking Connexin-43 may improve diabetic retinopathy, AMDFebruary 11th 2022
Dr David S. Boyer describes how blocking Connexin-43 may improve the retinal vascular system function in patients with diabetes, potentially creating a future of oral medication for treatment of diabetic retinopathy and AMD.